The greater efficacy of A-73209 antibiotic relative to Acyclovir / Aciclovir was especially apparent with oral dosing. The Norby Beirn Community Programs for Clinical zyrtec otc Research on AIDS (CPCRA).To examine the relationship between Acyclovir / Aciclovir use antibiotic and survival in AIDS, we performed a retrospective analysis of data collected through an observational cohort of the 17-site Community antibiotics coli Program for Clinical Research on AIDS (CPCRA), under the sponsorship of the National Institute of Allergy and Infectious Diseases. Efficacy of A-73209, a potent aciclovir orally antibiotics penicillin alcohol active agent against VZV and HSV infections.A-73209 is a novel oxetanocin derivative with potent in vitro and in vivo activity against VZV, HSV-1, and HSV-2. A-73209 was two logs more potent aciclovir than Acyclovir / Aciclovir against five thymidine kinase positive (TK ) strains of VZV in vitro (mean EC50 0.01 vs. The in vitro activity of A-73209 against thymidine kinase negative or deficient strains of VZV, HSV-1 and HSV-2 acyclovir was much lower than for the corresponding TK strains. Against HSV-2 infections in mice, the efficacy of A-73209 ranged from equal to 1.7 times less active relative to Acyclovir / Aciclovir acyclovir with oral dosing. Acyclovir / Aciclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of < 500/mm3.
After adjustments for differences antibiotics in baseline factors, Acyclovir / Aciclovir use was not associated with prolonged survival. A-73209 was orally bioavailable in mice, with maximal serum concentrations well in excess of in vitro inhibitory concentrations. A-73209 yielded a mean EC50 of 2.2 micrograms/ml compared to a mean EC50 of 0.37 micrograms/ml for Acyclovir / Aciclovir against a panel of TK HSV-2 strains in vitro.
A-73209 produced efficacy superior to Acyclovir / Aciclovir against lethal systemic or intracerebral HSV-1 infections in mice. A-73209 appears to be a potent and selective agent against varicella-zoster virus and herpes simplex virus infections.. Data were analyzed regarding 2,368 patients with CD4 lymphocyte counts of < 500/mm3, and 7,836 follow-up visits were conducted from September 1990 to July 1994. Factors associated with use of Acyclovir / Aciclovir were studied by stratified analysis of variance and Mantel-Haenzel chi 2 tests.
Individuals reporting Acyclovir / Aciclovir use were more likely to be white, male, and homosexual; to have a history of herpes simplex and zoster; and to have lower CD4 T cell counts than those who did not. The association between Acyclovir / Aciclovir and survival was studied with use of the proportional hazards regression model. The activity of A-73209 was one log more potent than Acyclovir / Aciclovir against TK HSV-1 strains in vitro (EC50 0.03 vs.
.